The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bristol-Myers Squibb; Genexine; Lilly
Consulting or Advisory Role - Bayer; ISU ABXIS
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); MacroGenics (Inst); Merck (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); Y-Biologics (Inst); Zymeworks (Inst)
Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
 
Zev A. Wainberg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Peter C. Enzinger
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Celgene; Daiichi Sankyo; loxo; Merck; Taiho Pharmaceutical; Takeda; Zymeworks
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Keun-Wook Lee
No Relationships to Disclose
 
Sang Cheul Oh
No Relationships to Disclose
 
Jin Li
No Relationships to Disclose
 
Haci Mehmet Turk
No Relationships to Disclose
 
Alexandra Carolina Teixeira
Research Funding - Five Prime Therapeutics
 
Giovanni Gerardo Cardellino
No Relationships to Disclose
 
Raquel Guardeño
Patents, Royalties, Other Intellectual Property - Five Prime Therapeutics
 
Siddhartha Mitra
Employment - Five Prime Therapeutics; Gilead Sciences
Stock and Other Ownership Interests - Five Prime Therapeutics; Gilead Sciences
 
Yingsi Yang
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics
 
Helen Collins
Employment - Five Prime Therapeutics
Leadership - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics
Other Relationship - Global Blood Therapeutics (I)
 
Daniel V.T. Catenacci
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus